Key result
Baseline serum sFas and sFasL fail to predict CKD progression in children.
Why the study?
Do serum and urinary levels of sFas, sFasL, and sE-selectin predict CKD progression in children?
Population
117 children with chronic kidney disease (CKD) and 56 healthy children
Design
Cohort
Follow-up
24 months
Authors
Loading...
Although sFas, sFasL, and sE-selectin levels are elevated in children with CKD, they do not serve as reliable predictors of disease progression.
Cohort (n=173)
Do serum and urinary levels of sFas, sFasL, and sE-selectin predict CKD progression in children?
Although sFas, sFasL, and sE-selectin levels are elevated in children with CKD, they do not serve as reliable predictors of disease progression.
Aksu et al. (2024) conducted a cohort in Chronic kidney disease (CKD) (n=173). sFas, sFasL, and sE-selectin levels vs. Healthy children and patients without rapid progression was evaluated on CKD progression. Baseline serum sFas and sFasL levels differed in patients with rapid CKD progression (P=0.045 and P=0.038), but these biomarkers did not serve as predictors of CKD progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: